Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)

ConclusionsConsistent with results seen with short-term treatment, long-term treatment with dupilumab showed an acceptable safety profile while providing incremental clinical benefit with continued treatment over time. The high proportion of patients who needed uptitration because of inadequate response to q4w dosing supports the q2w dose regimen as optimal for this age group. Finally, the majority of patients who stopped medication after having clear/almost clear skin sustained over 12  weeks experienced disease recurrence, suggesting the need for continued dupilumab dosing to maintain efficacy.Trial RegistrationClinicalTrials.gov Identifiers: NCT02612454, NCT02407756, NCT03054428, and NCT03050151.InfographicVideo abstract: What is the long-term safety and efficacy profile in adolescents with moderate-to-severe 98 atopic dermatitis treated with the approved dupilumab dose regimen? (MP4 40,966 KB)
Source: American Journal of Clinical Dermatology - Category: Dermatology Source Type: research